With keywords familiar to CGEN investors like "collaboration","novel", and "Drew Pardoll" (who said CGEN has the best immunoncology pipeline in the industry), how is the investment community failing to connect the dots here?
BTW, I watched "The Big Short" last night. We're just early, not wrong.
I see FPRX as similar in many ways other than Market Cap. For example, similar amounts of immune checkpoint discoveries, similar advisory board, etc.. But, the Market places much more value on FPRX vs. CGEN. I hope CGEN will close the gap over the next year ("short-term"). Long-term, I look at PCYC as a model to strive for.